1 week Ago By ABMN Staff
Vanguard Group Inc. lowered its stake in shares of Day One Biopharmaceuticals, Inc. ( NASDAQ:DAWN – Free Report ) by 0.
7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 5,848,923 shares of the company’s stock after selling 38,287 shares during the period.
Vanguard Group Inc. owned about 0.06% of Day One Biopharmaceuticals worth $74,106,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in DAWN. R Squared Ltd acquired a new position in Day One Biopharmaceuticals in the fourth quarter valued at $31,000. E Fund Management Co.
Ltd. purchased a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $143,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter worth $150,000.
XTX Topco Ltd purchased a new position in shares of Day One Biopharmaceuticals in the 3rd quarter valued at $178,000. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Day One Biopharmaceuticals by 20.9% during the 4th quarter.
Teacher Retirement System of Texas now owns 17,825 shares of the company’s stock valued at $226,000 after acquiring an additional 3,086 shares in the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.
Analyst Ratings Changes Several analysts recently issued reports on the company. JPMorgan Chase & Co. lowered their price target on Day One Biopharmaceuticals from $39.
00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. HC Wainwright reiterated a “buy” rating and set a $36.
00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, April 3rd. The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $39.00 to $27.
00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Bank of America lowered their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.
00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Finally, Wedbush reissued an “outperform” rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th.
Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $32.29.
Insider Activity at Day One Biopharmaceuticals In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 4,370 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $11.
96, for a total transaction of $52,265.20. Following the completion of the sale, the chief financial officer now owns 252,638 shares in the company, valued at $3,021,550.
48. The trade was a 1.70 % decrease in their ownership of the stock.
The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link . Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.
96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now directly owns 128,015 shares in the company, valued at $1,531,059.
40. This trade represents a 8.60 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders sold a total of 21,064 shares of company stock valued at $251,925 over the last three months. 8.
40% of the stock is owned by insiders. Day One Biopharmaceuticals Trading Down 7.0 % Day One Biopharmaceuticals stock opened at $6.
76 on Friday. The stock has a 50 day moving average of $9.44 and a 200-day moving average of $12.
09. The stock has a market cap of $685.16 million, a P/E ratio of -6.
56 and a beta of -1.24. Day One Biopharmaceuticals, Inc.
has a 52 week low of $6.41 and a 52 week high of $18.07.
Day One Biopharmaceuticals ( NASDAQ:DAWN – Get Free Report ) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.
35) by ($0.34). The business had revenue of $29.
21 million for the quarter, compared to analysts’ expectations of $27.11 million. As a group, equities analysts predict that Day One Biopharmaceuticals, Inc.
will post -0.72 earnings per share for the current fiscal year. Day One Biopharmaceuticals Profile ( Free Report ) Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.
Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. Further Reading Want to see what other hedge funds are holding DAWN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Day One Biopharmaceuticals, Inc.
( NASDAQ:DAWN – Free Report ). Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .
.
